Additionally, the unique high-field imaging capabilities of the MR-linac have the potential to make fMRI a standard component of the personalized therapies that cancer patients need. Ultimately, the combination of the technology with the clinical underpinning that is driving its development has the potential to result in significant outcome improvements that will truly benefit radiotherapy patients.
About the author: Dr. Joel Goldwein is a radiation oncologist and senior vice president, Medical Affairs, Elekta.
Back to HCB News
